Optibiotix Health Share Discussion Threads

[michaelmouse] 12/1/2017 08:31

1bokke - This is the gift that keeps on giving. Biggest faller today. Tertiary Minerals. I didn't really have to google it did I? Guess who tipped it at 4.13p?



An 86% loss then.

If you think they're better at shorting then pick some of AIM's best performers and I'll bet they've suggested shorting them at several points e.g. ASOS, ACSO, BOO etc.

You really couldn't make it up!!!!!!

[rafboy] 12/1/2017 08:21

Just have bought 3749 shares at 65.1p. Really believe in OPTI and not too long to wait until positive news in my view.

[michaelmouse] 12/1/2017 08:14

Opti released 45 RNS's last year. Nearly one per week. All supposedly positive? The share price tells its own story.

[whl2] 12/1/2017 08:14

Bet rafboy 'dips in' again today !

[neftanikoff] 12/1/2017 08:08

Please stop the preaching and simply answer the questions.

[1bokke] 12/1/2017 07:54

The gift that keeps on giving...

[michaelmouse] 12/1/2017 07:49

Not another pointless RNS. At least this one is RNS-NON. All this company does is PR.

"In order to provide us with wider coverage of our scientific advances in both the scientific and mainstream news media, we have appointed a specialist scientific PR company, Vane Percy & Roberts to help with this."

Puts to bed the idea that "so-called" partners will be paying for PR and Marketing. Clearly they're not. Opti are paying another PR agency and are also stumping up the money for any marketing of Go-Figure.

Both these markets will take multi-millions of marketing spend to achieve any foothold.

[parob] 12/1/2017 07:44

F3 I'm sure everything will become clear very soon. As has been discussed here before, our partners will want to announce new products as close to their launch date as possible. There will be nothing else like this on the market, all backed up by science/publications, and they aren't going to want their competitors to know in advance.

[john henry] 12/1/2017 07:43

And margins Rafboy.

[rafboy] 12/1/2017 07:37

Good to see this news. Having science backing our products will make a big difference to sales. I wonder if some pharmas will look more closely at OPTI?

[john henry] 12/1/2017 07:34

F3 I think all that information will follow very shortly. Stephen OHara must be absolutely flat out at present.Will be interesting to listen to the media interviews he's been doing this week.

[parob] 12/1/2017 07:27

Any marketing will be paid for by our partners anyway.Note the word 'anticipated' has now changed to 'planned' for the spring of 2017.

[f3rdinand] 12/1/2017 07:25

Considering the spring is so close, there are still a lot of unanswered questions about the cholesterol launch! Who are we partnered with? What products? Where will they be sold? Am very surprised under disclosure regulations they are allowed to be so secretive! Surely this is market sensitive?

[parob] 12/1/2017 07:21

So we can expect a strong media push as the cholesterol products are launched. IMO there will be a huge amount of coverage as these are natural products and have no side effects at a time when statins are receiving stacks of bad coverage. The word should spread so quickly that no (or very little) advertising will be needed (same as GoFigure). We're getting close now guys!

[someuwin] 12/1/2017 07:07

12 January 2017

OptiBiotix Health plc

("OptiBiotix" or the "Company")

Presentation of research data at European Conference: ProBiota 2017

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces that it has had two abstracts accepted for presentation at ProBiota 2017 in Berlin from 1-3 February 2017. ProBiota is the leading annual event for the global prebiotic, probiotic and the microbiota focused food and pharma industries. The conference is world renowned as a key meeting place for a community of scientists and business leaders who want to translate science into new products in the growing supplements and ingredients market.

The two abstracts relate to the work the Company has undertaken on its cholesterol lowering probiotic. The first abstract will cover the results of the clinical study and will be presented as a poster and oral presentation. The second abstract will be presented as a poster and covers the work on species specific microbiome modulators which the Company has used to enhance the cholesterol reducing effect of their cholesterol reducing strain (LP-LDL(R)). In the case of this strain, it leads to a threefold increase in the strains ability to lower cholesterol.

Commenting, Stephen O'Hara, CEO of OptiBiotix said: "These publications, at a major conference, will support the launch of a range of cardiovascular products to reduce LDL cholesterol, blood pressure and cardiovascular risk, planned for the spring of 2017. The publications will provide the scientific evidence for sales and marketing literature, which will help with product differentiation and higher margins. In order to provide us with wider coverage of our scientific advances in both the scientific and mainstream news media, we have appointed a specialist scientific PR company, Vane Percy & Roberts to help with this."

[adamb68] 11/1/2017 20:44

NeftI have been trading in LSE shares for many years and just had reasonable success at cfd trading but this takes up too much of my time. I'm no expert don't deal in huge amounts and just showing an interest in developing companies.This side is new to me and obviously you guys have plenty of knowledge once filtered out.So just showing interest and ADVFN seemed like a good place to start.

[elrico] 11/1/2017 19:45

Excellent post risky, other than speculate on applications, the addition I would make is royalties 7-15% and margins close to 100%. As AR eluded, the cost base is not likely to rise much, probably just on headcount because we don't manufacture or distribute and don't waste money of expensive office space. That said, it is worth expanding a little on your comments for any potential PI because it has not been touched on for some time.

On the cholesterol IP side, OPTI demonstrated the ability of its novel oligosaccharides to reduce cholesterol in human gut models by c20%. These sugars are heat resistant and stable during processing making them suitable as ingredients in a wide range of products. This finding extends the existing product opportunity offered by OptiBiotix's LP-LDL cholesterol reducing strain from supplements to ingredients, greatly increasing the market opportunity.

Slimbiome is on the cusp of a wave, be it in its infancy, but signs are SlimBiome is not just about supplement but has the ability to be used in a broad range of foods and OTC products, to which it is rumoured Tata will be the first MN to test these markets in Asia and China.

It is also worth revisiting the crossover in IP application for wealth multiplier; for example SlimBiome is an oligosaccharide. The oligosaccharides OptiBiotix is developing are a separate development to the weight management formulation. However, as with ALL OPTI platforms there are HIGH areas of OVERLAP which act as VALUE MULTIPLIERS. This means for a limited amount of extra cost we create large amounts of extra value. The sugars have no calories, sweetness, and functional properties (impact on satiation, body mass, cholesterol reduction etc). The current oligosaccharide used in SlimBiome has not been developed with these properties in mind.

OPTI will replace the oligosaccharide in SlimBiome with its own oligosaccharide. Replacing an ingredient in an existing commercial product fast tracks the commercial opportunity and allows them gain value from the SlimBiome product and the oligosaccharide ingredient. However, this is a small part of a bigger picture as once this is achieved the concept of introducing a low calorie, sweet, healthy functional oligosaccharide into a food product is established. As seen with the chancellors summer statement the replacement of unhealthy sugars (sucrose, fructose) with natural healthy sugars is an industry requirement. OPTI are in the box seat and well on the way to meeting that need.

In additional to their physical properties (sweetness etc) some of the oligosaccharides we are developing specifically increase the growth rate of individual microbial species. This is a large opportunity in its own right and is the basis of the deal with CSL and likely to lead to further commercial deals in the future.

Whilst this approach may seem complex having a number of platforms creating multiple opportunities substantially derisks the company. It’s a bit like having the Apple operating system being used in multiple products (Ipad, Iphone, Mac), you have multiple opportunities to succeed.

[neftanikoff] 11/1/2017 19:30

entirely agree 1bokke, his 'tactics' are always the same, his motive unclear to the ordinary man, strange.

[diamond fibre] 11/1/2017 19:28

It might count for zilch at the moment, but that's why the shares are 65p , you try to buy them in 3 months I bet you will pay more not less, the proof of the pudding is in the eating.

[1bokke] 11/1/2017 19:22

Neft, that's where I was going with my question. I suspect that he has a historical personal beef with someone and it has become a mission to do his bit to trash whatever interests this person. I find it very hard to believe that he is so naive about Opti's potential or about how free markets work, what I do find entertaining is his complete twisting of any facts to try to prove his points.

[primal123] 11/1/2017 19:18

Excellent post risky, potential is huge here, hopefully some positive news will come soon. Ps don't entertain the loser on the other thread. He doesn't have a clue.

[bobdown2] 11/1/2017 18:59

Risky...awesome post...thanks.

[neftanikoff] 11/1/2017 18:52

A very comprehensive reply, Risky business. I am afraid it will all fall on deaf ears for as far as he is concerned, unless a company is making profits and paying dividends, the upcoming potential and IP of a company counts for zilch. If that is his investment strategy, then fine but others have different strategies. But quite why he is so hung up with opti is strange.

[neftanikoff] 11/1/2017 18:41

That's another good question 1bokke. You might as well go on the DDDD b/b and all the other related such companies and share your concerns. Why pick out opti ?